Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Holding(s) in Company

5 May 2016 16:15

RNS Number : 4179X
Flying Brands Limited
05 May 2016
Β 

Β 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

Β 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

FLYING BRANDS LIMITED

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

Β 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

Β 

An event changing the breakdown of voting rights

Β 

Other (please specify):

Agreement for a concerted exercise of voting rights

Β 

3. Full name of person(s) subject to thenotification obligation: iii

Leon Hogan

4. Full name of shareholder(s)Β (if different from 3.):iv

Leon Hogan

5. Date of the transaction and date onwhich the threshold is crossed orreached:

29/04/16

6. Date on which issuer notified:

05/05/16

7. Threshold(s) that is/are crossed orreached: vi, vii

4%

Β Β Β Β Β Β Β 

Β 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

970,664

Β 970,664

1,270,664

1,270,664

Β 

4.11%

Β 

Β 

Β 

Β 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

Β 

Β 

Β 

Β 

Β 

Β 

Β 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

Β 

% of voting rights xix, xx

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Nominal

Delta

Β 

Β 

Β 

Β 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,270,664

4.11

Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β 

Β 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Β 

Β 

Β 

Proxy Voting:

10. Name of the proxy holder:

Β 

11. Number of voting rights proxy holder will ceaseto hold:

Β 

12. Date on which proxy holder will cease to holdvoting rights:

Β 

Β 

Β 

13. Additional information

Β 

14. Contact name:

Leon Hogan

15. Contact telephone number:

07939921333

Β Β Β Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLUGUWGAUPQGAA
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.